Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD8U | ISIN: US87650L1035 | Ticker-Symbol:
NASDAQ
06.06.25 | 22:00
43,920 US-Dollar
-0,39 % -0,170
1-Jahres-Chart
TARSUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TARSUS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur TARSUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOppenheimer assumes Tarsus stock at outperform on strong sales1
27.05.Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)2
27.05.H.C. Wainwright sets $72 target for Tarsus stock with Buy rating2
06.05.6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know2
02.05.Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign1
01.05.Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.64, revenue of $78.3M3
TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
01.05.Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements265Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position...
► Artikel lesen
01.05.Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
01.05.Tarsus Pharmaceuticals, Inc. - 8-K, Current Report1
30.04.An Overview of Tarsus Pharmaceuticals' Earnings2
24.04.Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 20251
22.04.Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ...1
13.03.Tarsus Pharmaceuticals, Inc. - 8-K, Current Report1
13.03.Tarsus prices $125M stock offering4
13.03.Tarsus Pharmaceuticals, Inc: Tarsus Announces Pricing of Upsized $125.0 Million Public Offering4
12.03.Tarsus Pharmaceuticals startet Aktienangebot im Wert von 100 Millionen US-Dollar 3
12.03.Tarsus Pharmaceuticals, Inc: Tarsus Announces Proposed $100.0 Million Public Offering2
06.03.Jefferies raises Tarsus stock target to $58, keeps Buy rating6
26.02.Tarsus stock holds Buy rating and $73 target at H.C. Wainwright2
25.02.Tarsus Pharmaceuticals, Inc. - 10-K, Annual Report-
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1